Are drugs manufactured in India safe? | In Focus podcast

Nakul Pasricha speaks to us on the manufacture and supply of drugs in India, and the recent global warning about the cough syrups manufactured in the country that were declared unsafe by the WHO. 

October 25, 2022 04:01 pm | Updated October 26, 2022 11:25 am IST

Earlier this month, the World Health Organisation issued a global warning about four cough syrups that it said were substandard products and were unsafe, and their use, especially in children, could “result in serious injury or death.” These four cough syrups Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup, were manufactured by Maiden Pharmaceuticals Ltd, based in Haryana. The medicines have been “potentially linked” with the deaths of over 60 children in The Gambia, a West African nation. The drugs, the WHO said, contained “unacceptable amounts” of two “contaminants”—diethylene glycol and ethylene glycol, which are toxic.

Diethylene glycol, which is generally used in industrial products, is believed to be used in medicines as an adulterant in order to cut costs. This is not the first instance of deaths due to diethylene glycol—there have been several cases in India too, the latest being the deaths of 14 children in Jammu in December 2019.

India is the largest manufacturer of generic drugs in the world, and supplies a range of drugs to 200-odd countries, meeting about half of the global vaccine demand. It supplies nearly 40% of the generic drugs demand in the United States and supplies about a quarter of all medicines in the United Kingdom. The industry is growing rapidly and will is estimated to be worth about 49 billion US dollars.

Explained | The Gambia deaths and the toxic cough syrups that are causing them

The Central Drugs Standard Control Organisation (CDSCO) and the Haryana State Drugs Controller have directed a stop to all manufacting activity at Maiden Pharmaceuticals Ltd following the Gambia deaths, and an expert committee has been constituted to look into this.

But where does the responsibility for drugs lie? Who enforces our laws on spurious drugs and are they enough? Do we have enough resources to check all of the drugs manufactured in India to ensure they are safe for consumers? What is the pharma industry’s role here and what is needed to ensure that no fake or substandard drug finds its way to a patient?

Guest: Nakul Pasricha, president and CEO, PharmaSecure, an organisation that works towards safety and authenticity in pharmaceuticals. Also, president, Authentication Solution Providers’ Association

Host: Zubeda Hamid

Edited by Sharmada Venkatasubramanian

Listen to more In Focus podcasts:

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.